LIFECORE BIOMEDICAL, INC. DE
No SEC Form 4 filings for $LFCR in the last 30 days.
See all $LFCR insider activity →Lifecore Biomedical set Nov. 4, 2026 as the record date for a special meeting to vote on its merger agreement. Stockholders of record on that date will vote at the meeting. The company will file proxy statements with the SEC. According to the company, proxy materials will be available on sec.gov and its investor relations site.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of Directors (the “
Hormel (HRL) acquires Brakebush for $1.06B; Onsemi (ON) to buy Synaptics for $5.7B; Leslie's files for bankruptcy. Valley National (VLY) to acquire Bluevine for $340M. Yext (YEXT) to acquire Flamel.ai. Lifecore (LFCR) to be acquired by Webster Equity for up to $663.7M. SoftBank completes DigitalBridge acquisition. GBTG acquired by Long Lake for $6.3B.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning LFCR (LIFECORE BIOMEDICAL, INC. DE). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent LFCR coverage spans mergers & acquisitions, earnings and corporate actions.
The announcement sets a clear timeline for shareholder approval of the merger, creating potential upside if the deal is confirmed and downside risk if dissent arises.
Potential upside if the merger is approved, but risk of pressure if shareholders reject or delay the deal.
Provides exit for shareholders; may boost valuation of similar biotech peers.
The amendment secures longer‑term revenue from Alcon and may be viewed positively by investors.
The deal provides a sizable cash premium, prompting the stock to trade near the offer price and likely rise on the news.
AlphAI scores every news story that mentions LFCR with an AI model for sentiment and relevance, and aggregates insider trades from LIFECORE BIOMEDICAL, INC. DE's SEC EDGAR Form 4 filings. Figures refresh continuously.
Lifecore Biomedical set Nov. 4, 2026 as the record date for a special meeting to vote on its merger agreement. Stockholders of record on that date will vote at the meeting. The company will file proxy statements with the SEC. According to the company, proxy materials will be available on sec.gov and its investor relations site.
1 min readLIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of Directors (the “
1 min readHormel (HRL) acquires Brakebush for $1.06B; Onsemi (ON) to buy Synaptics for $5.7B; Leslie's files for bankruptcy. Valley National (VLY) to acquire Bluevine for $340M. Yext (YEXT) to acquire Flamel.ai. Lifecore (LFCR) to be acquired by Webster Equity for up to $663.7M. SoftBank completes DigitalBridge acquisition. GBTG acquired by Long Lake for $6.3B.
3 min readLIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 24, 2026, Lifecore Biomedical, LLC (“Lifecore”), a subsidiary of Lifecore Biomedical, Inc. (the “Company”), entered into an Amendment No. 3 to Amended and Restated Contract Manufacturing Agreement (the “Third Amen
1 min readLifecore Biomedical (LFCR) agreed to be acquired by Webster Equity Partners for up to $663.7 million. The deal offers $6.28 per share plus a CVR, representing a 49.5% premium. The transaction, expected to close in Q4 2026, requires shareholder and regulatory approvals. Lifecore's stock will be delisted post-closing.
2 min readLIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Lifecore Biomedical to be Acquired by Webster Equity Partners • Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% Premium • Lifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share in
2 min readLifecore Biomedical (LFCR) reported Q2 2026 revenue of $34.2M, down 6.2% year over year, and a net loss of $6.2M ($0.19/share). Adjusted EBITDA was $8.6M. Gross margin fell to 35.3%. The company reaffirmed 2026 revenue guidance of $120M to $125M and adjusted EBITDA guidance of $20.5M to $25M, citing a 2027 demand inflection tied to Japanese market approval.
6 min readLifecore Biomedical (NASDAQ: LFCR) reported Q2 2026 revenues of $34.2M, down 6.2% year over year, and net loss of $6.2M ($0.19 per diluted share). Six-month revenues fell to $57.4M. Gross profit declined, while liquidity was about $38.8M. The company signed six new programs in Q2, added 13 over 12 months, and reaffirmed 2026 guidance.
6 min readLIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026 , and Provides Corporate Update -- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -- -- Cost Reduction and Productivity Enhanceme
6 min readLifecore Biomedical (NASDAQ: LFCR) said it signed three new customer agreements. One covers late-stage regenerative medicine technology transfer, engineering support, GMP readiness and PPQ services. Two are early-stage deals, including formulation optimization for a global medical technology company. Lifecore expects the programs to contribute to 2028 revenue.
2 min read
